Pharmaceutical synthesis containing 2,5-dihydrobenzofuran or one of its pharmaceutically acceptable salts in the form of a separate supplier and corresponding manufacturing procedure
A pharmacological synthesis containing 2,5-dihydrobenzo-p-sulfur or one of its pharmaceutically acceptable salts in the form of a personalized supply unit containing part of the acid or one of its salts, This is an immediate release component, the other is a long-term release component, which is characterized by an immediate release component consisting of between 8% P / P and 28% P / P, with respect to the total weight of the immediate release component, Another part of microcrystalline cellulose is a long-term release component, includingIn addition, in the total weight of long-term release, 10% of P / P to 45% of P / P, and 6.1% of P / P to 20% of P / P, in the total weight of long-term release, hydroxypropyl cellulose. Between the immediate release component and the long-term release component, this is between 24:76 and 40:60. He also mentioned the process of making the drug synthetic. It is used to reduce the fibrousness in human blood and to prevent and treat diseases caused by high doses of fibrousness,And the main variable state, chronic venous failure, etc., may be helpful to the treatment of diabetic retina.Referido a una composicion farmaceutica que comprende acido 2,5-dihidroxibencenosulfonico o una de sus sales farmaceuticamente aceptables en forma de unidades individualizadas de suministro； en donde una parte de dicho acido o una de sus sales, esta en forma de composicion de liberacion inmediata y otra parte esta en forma de composicion de liberacion prolongada； caracterizada porque dicha parte de composicion de liberacion inmediata comprende, adicionalmente entre un 8% p/p a 28% p/p, respecto del peso total de la parte de composicion de liberacion inmediata, de celulosa microcristalina； y otra parte esta en forma de composicion de liberacion prolongada, que comprende, adicionalmente entre un 10% p/p a 45% p/p, respecto del peso total de la parte de liberacion prolongada, de hidroxipropilmetilcelulosa y entre un 6,1% p/p a 20% p/p, respecto del peso to
